Price T Rowe Associates Inc. MD trimmed its position in Utah Medical Products, Inc. (NASDAQ:UTMD - Free Report) by 32.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 15,213 shares of the medical instruments supplier's stock after selling 7,227 shares during the quarter. Price T Rowe Associates Inc. MD owned about 0.45% of Utah Medical Products worth $936,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of UTMD. Barclays PLC raised its position in Utah Medical Products by 214.1% during the third quarter. Barclays PLC now owns 4,574 shares of the medical instruments supplier's stock valued at $306,000 after acquiring an additional 3,118 shares in the last quarter. JPMorgan Chase & Co. raised its position in Utah Medical Products by 10.6% during the third quarter. JPMorgan Chase & Co. now owns 69,411 shares of the medical instruments supplier's stock valued at $4,644,000 after acquiring an additional 6,645 shares in the last quarter. SG Americas Securities LLC purchased a new position in Utah Medical Products during the fourth quarter valued at approximately $157,000. R Squared Ltd purchased a new position in Utah Medical Products during the fourth quarter valued at approximately $49,000. Finally, Golden State Wealth Management LLC purchased a new position in Utah Medical Products during the fourth quarter valued at approximately $31,000. 69.60% of the stock is currently owned by hedge funds and other institutional investors.
Utah Medical Products Trading Down 0.8%
UTMD traded down $0.47 during trading on Friday, hitting $54.39. The company's stock had a trading volume of 1,377 shares, compared to its average volume of 19,703. Utah Medical Products, Inc. has a twelve month low of $51.26 and a twelve month high of $77.33. The business's fifty day simple moving average is $54.61 and its 200 day simple moving average is $59.78. The firm has a market capitalization of $178.49 million, a price-to-earnings ratio of 13.77 and a beta of 0.30.
Utah Medical Products (NASDAQ:UTMD - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The medical instruments supplier reported $0.92 EPS for the quarter. Utah Medical Products had a return on equity of 11.07% and a net margin of 33.92%. The company had revenue of $9.71 million for the quarter.
Utah Medical Products Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 3rd. Shareholders of record on Monday, June 16th will be issued a $0.305 dividend. This represents a $1.22 annualized dividend and a yield of 2.24%. The ex-dividend date of this dividend is Monday, June 16th. Utah Medical Products's payout ratio is currently 32.28%.
About Utah Medical Products
(
Free Report)
Utah Medical Products, Inc develops, manufactures, and distributes medical devices for the healthcare industry worldwide. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems.
Featured Articles
Before you consider Utah Medical Products, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Utah Medical Products wasn't on the list.
While Utah Medical Products currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
